MiR-192-5p reverses cisplatin resistance by targeting ERCC3 and ERCC4 in SGC7901/DDP cells
Xiaoque Xie(Anhui Medical University), Kangsheng Gu(Anhui Medical University), Mengru Gao(Anhui Medical University), Qihong Zhao(Anhui Medical University), Hua Wang(Anhui Medical University), Yiyin Zhang(Peking University), Min Li(Anhui Medical University), Jie Ning(Peking University First Hospital), Xiaoli Wei(Anhui Medical University), Wei Liu(Sun Yat-sen University), Nana Huang(Anhui Medical University)
Cited by 35
Related Papers
Erythrocyte–Platelet Hybrid Membrane Coating for Enhanced Nanoparticle Functionalization
|Advanced Materials|2017|756
Camrelizumab plus carboplatin and pemetrexed versus chemotherapy alone in chemotherapy-naive patients with advanced non-squamous non-small-cell lung cancer (CameL): a randomised, open-label, multicentre, phase 3 trial
|The Lancet Respiratory Medicine|2020|504
Safety, efficacy and tumor mutational burden as a biomarker of overall survival benefit in chemo-refractory gastric cancer treated with toripalimab, a PD-1 antibody in phase Ib/II clinical trial NCT02915432
|Annals of Oncology|2019|475